Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lurasidone→

Lurasidone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
367514-87-2
Molecular formula
C28H36N4O2S
Molecular weight
492.7 g/mol
Drug class
Atypical AntipsychoticAntipsychotic
Mechanism of action
The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear.
Indications / reported uses
  • Bipolar Disorder
  • Major Depressive Disorder
  • Schizophrenia

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lurasidone Environmental Risk Assessment (ERA) (the Lurasidone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.